Oral Antidiyabetiklerle 4 Senelik Tecrübe

Year 1961, Volume: 14 Issue: 1, 45 - 49, 28.02.1961

Cavit Sökmen

https://izlik.org/JA59JP32NK

Abstract

Oral antidiabetic agents spare patients from daily injections, yet they still fall short of meeting all therapeutic needs. Over a 4-year period, we treated 70 diabetic cases with various oral antidiabetics. Carbutamide was discontinued due to its toxicity. Tolbutamide showed minimal side effects and a 66% success rate. Chlorpropamide, though potent, required careful monitoring due to adverse reactions and achieved a 60% success rate. Biguanide derivative DBI showed mild hypoglycemic effect with promising results in adult-type diabetes but failed to stabilize juvenile-type diabetes. Despite limitations, tolbutamide appears to hold a favorable position among current agents.

Keywords

oral antidiabetics , sulfonylureas , tolbutamide , chlorpropamide , biguanides

Four-Year Experience with Oral Antidiabetic Agents

https://izlik.org/JA59JP32NK

Abstract

Oral antidiyabetikler hastayı günlük enjeksiyonlardan kurtarmakta ise de henüz ideal niteliklere ulaşamamıştır. 4 yıllık sürede 70 diyabet vakasında çeşitli oral antidiyabetikler kullanılmıştır. Karbütamid toksik etkileri nedeniyle terk edilmiştir. Tolbutamid düşük yan etki oranı ve %66 başarı oranı ile öne çıkmıştır. Klorpropamid güçlü hipoglisemik etkisine rağmen yan etkileri nedeniyle dikkatle kullanılmalıdır; başarı oranı %60’tır. Biguanid türevi DBI, erişkin tip diyabette umut verici sonuçlar vermiştir ancak juvenil diyabette glisemi dalgalanmalarını kontrol edememiştir. Mevcut ajanlar arasında tolbutamid daha iyi bir konumda görünmektedir.

References

• Bertram, T. Experiences recueillies sur 1000 diabetiques traites par les sulfonylurees (BZ 55 et D 860). La Gaz. Med. de France 1957, 6, 519.
• Hedon, L., Loubatieres, A. Les sulfamides hypoglycemiants et leur interet pour le traitement du diabete. Ann. d'Endocr. 1957, 18-4, 477.
• Hoet, J. P. Conclusions a propos de l'emploi des sulfamides hypoglycemiants en clinique humaine. Ann. d'Endocr. 1957, 18-2, 396.
• Hunt, J. A., Oakley, W. Clinical trial of the new oral hypoglycaemic agent BZ 55. Br. Med. Jour. 1956, 4960, 445.
• Jersild, M. Quelques experiences cliniques sur des substances hypoglycemiantes orales. Ann. d'Endocr. 1957, 18-2, 271.
• Kaldor, A., Pogatsa, G. The mode of action of oral antidiabetic compounds. Lancet 1959, 7069, 386.
• Krall, L. P. Clinical use of Biguanide and their role in stabilizing juvenile-type diabetes. Diabetes 1958, 7, 468.
• Loubatieres, A. La contribution française a la decouverte des proprietes hypoglycemiantes et antidiabetiques de certains sulfamides. La Gaz. Med. de France 1957, 6, 505.
• Loubatieres, A. Le mecanisme d'action des sulfamides hypoglycemiants et de leurs derives. Ann. d'Endocr. 1957, 18-2, 161.
• Loubatieres, A. Action des sulfamides hypoglycemiants et de leurs derives chez l'homme diabetique. Ann. d'Endocr. 1957, 18-2, 260.
• Male, A. Symposium on "A new oral hypoglycemic agent phenformin (DBI)". Diabetes 1960, 9-3, 225.
• Murray, I. Chlorpropamide. Lancet 1958, 2, 553.
• Stowers, J. M., Mahler, R. F. Pharmacology and mode of action of the sulphonylureas in man. Lancet 1958, 7015, 278.
• A. U. Tıp Fak. Mec. XIV, 4